We aim to develop the world’s first mucosally-targeted therapeutic and pre-exposure prophylactic antibody aimed at treating COVID-19, and blocking transmission and preventing new infections, respectively.
2022-2024
Our strategy is to develop two products: (1) an intramuscular or intravenous delivered purified antibody for the treatment of COVID-19 or use as a long-lasting prophylactic to supplement existing immunity; and (2) an inhalable version of the antibody for the prevention of SARS-CoV-2 infection.
Our antibody system is a platform technology that could be adapted for other pathogens for which no vaccines or treatments are currently available. These include norovirus, RSV, and other enteric and mucosal pathogens.
Funding
Partners
- DJPR
Project
Team
Meet the project team. Together, we are translating research into better health, for all.
